De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867005847352115200 |
|---|---|
| author | Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra |
| author_facet | Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra |
| collection | Wiley Open Access |
| contents | De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra Clinical Transplantation ABSTRACT Background Cytomegalovirus (CMV) is associated with morbidity and mortality after a kidney transplant (KT). Letermovir (LTV) was approved in high‐risk KT recipients, providing an alternative to standard‐of‐care valganciclovir (VGC) associated with reduced myelosuppression. Methods Adult patients receiving a kidney transplant with moderate‐risk CMV serostatus between 1/1/2021 and 6/6/2024 were evaluated. Patients were included in VGC or LTV cohort based on de novo prophylaxis regimen. The primary outcomes were efficacy and tolerability. Results Four hundred and eight KTRs met inclusion criteria: 316 received VGC, 92 received LTV. Cohorts were comparable; the majority received a primary (84.2% vs. 90.2%, p = 0.566) deceased donor (69.6% vs. 68.5%, p = 0.298) transplant with lymphocyte depleting induction (82.3% vs. 90.2%, p = 0.32). Significantly more patients in the VGC cohort required antiviral dose adjustment (61.7% vs. 1.1%, p < 0.0001). Patients in the LTV cohort were significantly more likely to complete antiviral prophylaxis (63.3% vs. 84.8%, p < 0.0001). Patients in the VGC cohort were significantly more likely to experience leukopenia (65.8% vs. 45.7%, p = 0.0006) and neutropenia (30.7% vs. 12.0%, p = 0.0002) during the first‐year post‐KT. Significantly more patients in the LTV cohort were on the equivalent of >1000 mg mycophenolate/day at 12 months post‐KT (59.9% vs. 74.2%, p = 0.0173). Rates of CMV viremia and clinically significant disease through 1‐year post‐KT were comparable. Conclusions De novo LTV in R+ KTRs appears to be safe and effective compared to VGC. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and requires less dose titration. Additionally, LTV appears to be associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization. 10.1111/ctr.70423 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.70423 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_70423 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra Clinical Transplantation De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care Hanna L. Kleiboeker Margaret R. Jorgenson Michael J. Scolarici Jillian L. Descourouez Glen E. Leverson Chris Saddler Didier Mandlebrot David Al‐Adra Clinical Transplantation ABSTRACT Background Cytomegalovirus (CMV) is associated with morbidity and mortality after a kidney transplant (KT). Letermovir (LTV) was approved in high‐risk KT recipients, providing an alternative to standard‐of‐care valganciclovir (VGC) associated with reduced myelosuppression. Methods Adult patients receiving a kidney transplant with moderate‐risk CMV serostatus between 1/1/2021 and 6/6/2024 were evaluated. Patients were included in VGC or LTV cohort based on de novo prophylaxis regimen. The primary outcomes were efficacy and tolerability. Results Four hundred and eight KTRs met inclusion criteria: 316 received VGC, 92 received LTV. Cohorts were comparable; the majority received a primary (84.2% vs. 90.2%, p = 0.566) deceased donor (69.6% vs. 68.5%, p = 0.298) transplant with lymphocyte depleting induction (82.3% vs. 90.2%, p = 0.32). Significantly more patients in the VGC cohort required antiviral dose adjustment (61.7% vs. 1.1%, p < 0.0001). Patients in the LTV cohort were significantly more likely to complete antiviral prophylaxis (63.3% vs. 84.8%, p < 0.0001). Patients in the VGC cohort were significantly more likely to experience leukopenia (65.8% vs. 45.7%, p = 0.0006) and neutropenia (30.7% vs. 12.0%, p = 0.0002) during the first‐year post‐KT. Significantly more patients in the LTV cohort were on the equivalent of >1000 mg mycophenolate/day at 12 months post‐KT (59.9% vs. 74.2%, p = 0.0173). Rates of CMV viremia and clinically significant disease through 1‐year post‐KT were comparable. Conclusions De novo LTV in R+ KTRs appears to be safe and effective compared to VGC. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and requires less dose titration. Additionally, LTV appears to be associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization. 10.1111/ctr.70423 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70423 |